IFN-β-R27T showed a similar or slightly weak inhibitory effect on cancer cells compared to trastuzumab-R27T, indicating that the antitumor effect of trastuzumab-R27T is mainly due to IFN-β than that of trastuzumab. The gene discussed is IFNB1; the disease is cancer.